Purple Biotech (PPBT) News Today $2.27 +0.07 (+3.18%) Closing price 05/16/2025 03:46 PM EasternExtended Trading$2.26 -0.01 (-0.44%) As of 05/16/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PPBT Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Purple Biotech Appoints Shai Lankry as Chief Financial Officer to Drive Strategic Growth and Financial ExcellenceMay 13, 2025 | nasdaq.comPurple Biotech appoints Shai Lankry as new CFOMay 13, 2025 | investing.comPurple Biotech Ltd.: Purple Biotech Appoints Shai Lankry as Chief Financial OfficerMay 12, 2025 | finanznachrichten.dePurple Biotech Appoints Shai Lankry as Chief Financial OfficerMay 12, 2025 | globenewswire.comPurple Biotech Unveils Promising Phase 2 Results for CM24 in Pancreatic CancerApril 30, 2025 | tipranks.comPurple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck CancersApril 28, 2025 | globenewswire.comPurple Biotech announces publication of study on potential of NT219April 17, 2025 | markets.businessinsider.comPurple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research MeetingMarch 28, 2025 | finance.yahoo.comPurple Biotech Unveils Updated Oncology Pipeline ProgressMarch 18, 2025 | tipranks.comPurple Biotech Reports Positive Clinical Trial Results for CM24 and NT219, Advancing to Phase 2 StudiesMarch 12, 2025 | nasdaq.comPurple Biotech reports Q4 EPS (26c) vs. ($3.80) last yearMarch 10, 2025 | markets.businessinsider.comPurple Biotech sees cash runway into mid-2026March 10, 2025 | markets.businessinsider.comPurple Biotech Reports Fourth Quarter and Full-Year 2024 Financial ResultsMarch 10, 2025 | globenewswire.comPurple Biotech granted new U.S. patent for NT219March 5, 2025 | markets.businessinsider.comPurple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major MarketsMarch 5, 2025 | markets.businessinsider.comPurple Biotech advances NT219 into Phase 2 head, neck cancer trialFebruary 18, 2025 | markets.businessinsider.comPurple Biotech Advances NT219 into Phase 2 Head and Neck Cancer TrialFebruary 18, 2025 | globenewswire.comPurple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody PlatformFebruary 4, 2025 | markets.businessinsider.comPurple Biotech announces research collaboration with Icahn School of MedicineFebruary 4, 2025 | markets.businessinsider.comPurple Biotech Ltd. American Depositary Shares (PPBT)December 5, 2024 | nasdaq.comPurple Biotech Ltd. Closes $2.8 Million Registered Direct Offering of American Depositary SharesDecember 5, 2024 | quiverquant.comPurple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary SharesDecember 5, 2024 | globenewswire.comPurple Biotech Secures $2.8 Million Through ADS OfferingDecember 4, 2024 | markets.businessinsider.comPurple Biotech to sell 472,668 ADSs at $6.00 in registered direct offeringDecember 4, 2024 | markets.businessinsider.comWhy Purple Biotech (PPBT) Stock Is Getting HammeredDecember 4, 2024 | benzinga.comPurple Biotech Announces $2.8 Million Registered Direct Offering of American Depositary SharesDecember 3, 2024 | globenewswire.comPurple Biotech reports final results from randomized Phase 2 study of CM24December 2, 2024 | markets.businessinsider.comPurple Biotech Shares Jump on Positive Phase 2 Cancer Drug Study ResultsDecember 2, 2024 | marketwatch.comPurple Biotech Reports Positive Final Data From Phase 2 Study Of CM24 In Pancreatic Cancer; Stock UpDecember 2, 2024 | markets.businessinsider.comPurple Biotech Stock Hits Nearly 2-Month High On Cancer Drug Trial Success: Retail ThrilledDecember 2, 2024 | msn.comPurple Biotech Reports Positive Final Results from Randomized Phase 2 Study of CM24 in Second Line Pancreatic CancerDecember 2, 2024 | markets.businessinsider.comPurple Biotech Ltd.: Purple Biotech Reports Third Quarter 2024 Financial ResultsNovember 16, 2024 | finanznachrichten.dePurple Biotech reports Q3 EPS (39c) vs ($4.63) last yearNovember 16, 2024 | markets.businessinsider.comPromising Interim Results Propel Purple Biotech’s Buy Rating Amid Phase 2 Success and Strategic AdvancementsNovember 16, 2024 | markets.businessinsider.comPurple Biotech Ltd. Reports Progress in Phase 2 CM24 Pancreatic Cancer Trial and Biomarker Developments, Financial Results for Q3 2024November 15, 2024 | quiverquant.comPurple Biotech Reports Third Quarter 2024 Financial ResultsNovember 15, 2024 | globenewswire.comPurple Biotech Unveils Promising Biomarker for Cancer TherapyNovember 5, 2024 | finance.yahoo.comPurple Biotech identifies potential new serum biomarker for CM24November 4, 2024 | markets.businessinsider.comPurple Biotech Identifies Potential New Serum Biomarker for its Lead Oncology Therapeutic Candidate CM24: Associated with 79% Reduction in Risk of DeathNovember 4, 2024 | globenewswire.comPurple Biotech (NASDAQ:PPBT) Stock, Option ChainNovember 3, 2024 | benzinga.comPurple Biotech (NASDAQ:PPBT) Stock, Short Interest ReportNovember 2, 2024 | benzinga.comPurple Biotech Advances with CAPTN-3 Cancer PlatformOctober 25, 2024 | markets.businessinsider.comPurple Biotech Presents New Data for its Novel Tri-Specific T Cell and NK Cell Engagers Antibody Platform, CAPTN-3, at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsOctober 25, 2024 | globenewswire.comPurple Biotech Unveils CAPTN-3 Cancer TherapyOctober 11, 2024 | finance.yahoo.comPurple Biotech to Present Data for its Tri-Specific Antibody Platform—CAPTN-3—at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsOctober 10, 2024 | globenewswire.comPurple Biotech (NASDAQ:PPBT) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comQ3 2024 EPS Estimates for Purple Biotech Ltd Reduced by Analyst (NASDAQ:PPBT)Purple Biotech Ltd (NASDAQ:PPBT - Free Report) - Analysts at HC Wainwright cut their Q3 2024 EPS estimates for Purple Biotech in a research report issued on Thursday, September 19th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($1.20) per share for the quarter, down fSeptember 23, 2024 | marketbeat.comPurple Biotech (NASDAQ:PPBT) PT Raised to $33.00 at HC WainwrightHC Wainwright upped their price target on Purple Biotech from $8.00 to $33.00 and gave the stock a "buy" rating in a research note on Friday.September 20, 2024 | marketbeat.comBuy Rating Justified by Promising CM24 Phase 2 Study for Pancreatic Cancer SurvivalSeptember 19, 2024 | markets.businessinsider.comPurple Biotech Reports Additional Positive Interim Data from its Randomized Phase 2 Study with its Lead Oncology Therapeutic Candidate CM24September 18, 2024 | globenewswire.com Get Purple Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter. Email Address PPBT Media Mentions By Week PPBT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PPBT News Sentiment▼0.190.60▲Average Medical News Sentiment PPBT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PPBT Articles This Week▼41▲PPBT Articles Average Week Get Purple Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Imunon News Today Minerva Neurosciences News Today BriaCell Therapeutics News Today Bright Green News Today Cellectar Biosciences News Today Affimed News Today Abpro News Today Lakeshore Biopharma News Today Talphera News Today PHAXIAM Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PPBT) was last updated on 5/18/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowMusk has launched a bold new AI initiative—and while you can’t invest in it directly, one overlooked stock cou...Behind the Markets | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Two drop-dead simple ways to play the gold boomIf you take a few minutes to check out the short research briefing Mark & I have put together, I’m confident y...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Purple Biotech Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Purple Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PPBT Stock Free PPBT Stock Alerts